Key Takeaways

Ozempic, Wegovy, Zepbound and similar drugs may drop to $245 to $350 a month for eligible folks

The pricing applies to Medicare, Medicaid and a program launching later this year called TrumpRx

About 10% of Medicare patients are expected to qualify for the new lower prices

FRIDAY, Nov. 7, 2025 (HealthDay News) — Two major drugmakers will slash the price of popular weight loss medications for some Americans, including people on Medicare and Medicaid, President Donald Trump announced Thursday.

The deal involves Eli Lilly , which makes Zepbound and Mounjaro , and Novo Nordisk , the maker of Ozempic and Wegovy .

The drugs, known as GLP-1 medications, now cost as much as $1,350 a month. Under the agreement, eligible patients will pay around $245 to $350 per mont

See Full Page